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ABSTRACT 
Studying human brain development and disorders is very challenging. In the absence of 
comparable model organisms, human-related models, and limitations to obtain live cells from 
the human brain, induced Pluripotent Stem Cell (iPSC) technology, in particular, provided a 
unique tool to study the disease mechanisms and investigate potential treatments. The main 
goal of this thesis was to study neurological disorders and explore novel mechanisms 
underlying the diseases. 
We have generated and characterised patient and healthy control iPSCs using Sendai virus as 
a safe non-integrating method to keep the host genome intact. We have then shown an example 
of a standardised culture condition by using recombinant spider silk coating for iPSCs and 
Embryonic Stem Cells (ESCs) cultivation in 2D and 3D formats. Healthy Pluripotent Stem 
Cell lines cultured on recombinant spider silk displayed the typical stem cell morphology with 
the expression of pluripotent stem cell markers. Considering the xeno-free culture coating and 
compatibility with the host immune system, the spider silk, can provide an optimal routine 
culture system for pluripotent stem cells and future iPSC based therapies. 
Patient and healthy iPSCs were neurally induced to generate intermediate, expandable 
Neuroepithelial Stem Cell (NESC) lines. Morphologically, the derived NESCs displayed 
rosette structures in culture and expressed key neural stem cell markers. Also, the 
transcriptomic profile of derived lines displayed similarity that proposes the homogeneity of 
our NESC population despite patient genomic background variation. We have used a healthy 
control NESC line to model Alzheimer’s Disease (AD) in a dish by exogenous application of 
amyloid beta oligomers in differentiating culture. Interestingly, AD-related phenotype, dis-
localisation of phosphorylated P21-activated kinases (pPAK) protein, was recapitulated only 
in 3D culture. 
We further attempted to identify mechanisms underlying Type 1 Lissencephaly from patients 
carrying Doublecortin (DCX) mutations. Differentiating patients’ cells with dis-regulation of 
DCX expression exhibited a migrational defect, aberrant neurite outgrowth, and fewer dendrite 
bundles. In addition, we have dissected a proliferation phenotype of DCX mutant cells upon 
differentiation. Data suggests an indispensable role of DCX expression at an early stage of 
neural development which allows proper differentiation and migration. 
Here we have shown that it is possible to make a robust cellular model to study human brain 
disorders using patient-specific cells. Identification and verification of disease phenotypes and 
exploring the underlying mechanisms could provide valuable insights into these complex 
disorders. These insights may offer novel approaches to therapeutic applications taking 
scientists one step closer to treating the patients. This study underlines the importance of 
cellular-based models, 2D and 3D, that can be used to study typical development as well as 
disease mechanisms. 
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1 THE STUDY OF HUMAN BRAIN DEVELOPMENT AND 
DISORDERS; CHALLENGES AHEAD 
Studying the human brain has always been complicated. Besides ethical issues, it is not feasible 
to directly study the human brain due to its location and inaccessible anatomy. Understanding 
mechanisms of human brain disorders, specifically those with a developmental origin, have 
been very challenging, as taking live cells from patients is very rare. Moreover, postmortem 
samples are not commonly available and give limited information. Although animal model 
studies reveal precious information, it is not easy to translate animal data to human, due to 
species differences, the complexity of the human brain, and diseases related solely to the human 
brain. There is a need for cellular models that mimic the human brain to study and understand 
the mechanisms underlying the disease and reduce the hindrances in development of new 
treatments. 
After successes in culturing embryonic stem cell (ESC) lines from inner cell mass of mouse 
blastocyst by Matthew Kaufman and Martin Evan [1] and Gail Martin [2] in 1981 and later on 
of human by Thomson and colleagues [3], ESCs have been used as an amenable tool to study 
the developmental process as well as disease mechanisms with the perspective of applying 
them as a source of transplantation and therapeutic purposes. In vitro culture of pluripotent 
ESCs revealed their limitless self-renewal capacity and differentiation potential into the three 
germ layers; ectoderm, endoderm, and mesoderm. Some studies have used ESCs to investigate 
the normal development and disease mechanisms such as Fragile X Syndrome and Lesch-
Nyhan disease [4], [5]. Due to limitations in using ESCs, such as ethical implications, hESCs 
accessibility, and availability, there was an unmet demand for an in vitro, unlimited, available, 
and autologous source of cells that could feasibly be generated and accessible in the lab. 
Shinya Yamanaka made this possible and was deservedly awarded the Nobel Prize in 
Physiology and Medicine 2012 jointly with Professor John Gurdon. In 2006 Yamanaka and his 
colleague introduced a combination of essential pluripotent genes into fibroblasts, first in 
mouse [6] and later in human fibroblasts [7]. He was able to turn back the developmental clock 
from fully differentiated cells to the embryonic stage. He started with ectopic co-expression of 
24 pluripotency-associated candidate genes that eventually narrowed down to just four factors; 
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Oct4 (Pou5f1), Sox2, Klf4, and c-Myc. Reprogrammed cells were termed induced pluripotent 
stem cells (iPSCs) by Yamanaka. Thomson laboratory also reported the successful human 
fibroblast reprogramming by using 4 transcription factors Oct4, Sox2, Nanog, and Lin28 in the 
same year [8]. 
iPSCs resemble ESCs with respect to morphology, gene expression profile, and expression of 
cell surface markers. iPSCs are pluripotent; they have unlimited self-renewal capacity and the 
ability to differentiate into the three germ layers; ectoderm, endoderm, and mesoderm. 
Reprogramming from a wide range of somatic cells from human enables scientists to generate 
induced pluripotent stem cells in the lab. iPSCs have been shown to be equivalent to human 
embryonic stem cells which makes them a perfect in vitro model to study human development 
in a dish. 
By reprogramming somatic cells, typically fibroblasts, we have been able to derive patient-
specific stem cells. With access to patient-specific iPSCs, we can further differentiate them 
towards specific cell types relevant to the disease. Studies evaluating impaired neurogenesis 
and migration, neuronal connectivity, synaptic plasticity and functional electrophysiology 
would be valuable in order to understand disease-related phenotypes [9], [10]. Besides 
modelling disease, iPSCs can be used in drug discovery to screen possible drugs or develop 
where they cannot be tested in humans [9] and even the possibility to develop tailored 
treatments. Moreover, they have therapeutic potential and are considered good candidates for 
autologous cell transplantation [11]. A future perspective would be to apply gene targeting for 
known mutations, to create iPSCs with corrected DNA and differentiate them to the affected 
cell type, which would finally allow healthy cells to be transplanted back to the patient [12], 
[13].  
In recent years, several neurological disorders have been modeled using iPSCs such as Autism 
Spectrum Disorders (ASDs) [14], [15], Timothy Syndrome (TS) [16], Fragile X Syndrome 
(FXS) [17], [18], Rett Syndrome (RTT) [19], Down Syndrome (DS) [20], [21], Alzheimer’s 
Disease (AD) [22], [23], Amyotrophic Lateral Sclerosis (ALS) [24], [25], Schizophrenia (SZ) 
[26], and the number is growing, showing how powerful the technique is to recapitulate and 
discover the disease-related phenotypes and use the knowledge to hopefully help patients with 
such complex diseases.  
  3 
  
A typical induced pluripotent stem cell (iPSC) colony on laminin-521 coating 
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2 INDUCED PLURIPOTENT STEM CELLS 
Reprogramming occurs through key sequential events at cellular and molecular levels reviewed 
in [27]. During the initiation phase, somatic cell signature is lost via downregulation of somatic 
differentiation genes, leading to morphological changes of the cells known as MET 
(mesenchymal to epithelial transition). At the same time, upregulation of pluripotency markers 
such as SSEA1 and alkaline phosphatase (AP) appear. Transduced cells gain proliferation 
capacity likened to ESC’s, as well as inhibition of apoptosis and senescence, due to the vast 
transcriptional changes induced by the reprogramming factors. It has been shown that 
transcription factors Oct4, Sox2, and Klf4 act as ‘‘pioneer factors’’ and initially bind to inactive 
DNA regions with the c-Myc cooperation to turn on pluripotency. Moreover, c-Myc binds to 
open chromatin regions suppressing fibroblast-specific genes [28], [29]. Next comes 
maturation phase with the gradually increased expression of some pluripotency markers such 
as NANOG and endogenous OCT4. During the final phase, cells that passed the maturation 
phase acquire a pluripotency signature by expressing a second subset of pluripotency genes 
such as SOX2, resulting in the production of bona fide iPSCs that are independent of ectopic 
expression of reprogramming factors. 
The epigenetic reprogramming is as crucial as the gene reset during the reprogramming 
process. It is believed that epigenetic reprogramming begins with global demethylation of 
different genes before the actual gene silencing and activation occur. The global gene 
demethylation is prior to the functioning of the reprogramming factors. This is mainly mediated 
by ESC-specific microRNAs such as micR-302 family [30], [31]. 
iPSCs have unlimited self-renewal capacity, express pluripotent stem cell markers including 
cell surface markers TRA1-60 and TRA1-81 and pluripotent cell nuclei markers OCT4 and 
NANOG. The differentiation potential of iPSC lines is assessed in vitro by embryoid bodies 
(EB) formation and in vivo by teratoma formation. A potential replacement to teratoma assay 
which has been recently introduced is Pluritest; a bioinformatics and noninvasive method. 
PluriTest is a panel of around 450 genome-wide transcriptional profiles of which 223 are hESC 
lines and 41 are hiPSC lines, and the rest are from various differentiated cell types and tissues 
from developing and adult human all from a variety of laboratories [32]. 
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The first generation of iPSC lines did not display fully reprogrammed cells equivalent to ESCs. 
The DNA methylation status and gene expression patterns of derived lines were different to 
ESC lines; the promoter of key reprogramming mediators such as Oct4 displayed incomplete 
demethylation [6]. After uncovering these imperfections, Yamanaka and other laboratories 
attempted to redesign the experiment and improve the technique. They successfully 
demonstrated the high similarity of iPSCs and ESCs at the epigenetic state and transcriptional 
profile [33], [34]. It has been shown that besides morphology and functional similarity between 
iPSCs and ESCs, the epigenetic state and transcriptional profile are both highly similar [34]. 
It is believed that reprogramming itself is not a primary issue that causes differences in derived 
iPSC lines, but rather other technical factors including transduction method and culture 
conditions. Due to the events during reprogramming that cannot be controlled, it is important 
to select good iPSC clones to obtain a proper cellular model [35]. 
Here I discuss two important fundamental factors that directly affect reprogramming leading 
to a complete and perfect iPSC generation; the gene delivery method and culture condition. 
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2.1 INTEGRATION-FREE MEDIATED REPROGRAMMING 
The induction method greatly affects the efficiency of reprogramming and the quality of 
derived iPSCs. Yamanaka used retrovirus to introduce pluripotency genes into fibroblasts. 
Since then, reprogramming has been performed with multiple methods such as lentivirus, 
adenovirus, plasmids, transposons, Sendai virus, protein delivery, microRNA, and chemical 
compounds [12]. Retrovirus and lentivirus, initially the most commonly used, are enveloped 
single-stranded positive-sense RNA viruses. Upon entering the host cell, their RNA is reverse-
transcribed into DNA, which is then integrated into the host genome, followed by the regular 
transcription and translational processes to express the genes carried by the virus. The genomic 
integration can cause insertional mutagenesis, disrupt the target cells, and alter gene expression 
patterns, which can compromise drug screens, disease pathway analyses, and also increase the 
risk of tumorigenesis. Additionally, these vectors have very low efficiency 0.001-1%; the 
number of resulting iPSC colonies per the number of infected cells seeded gives us the 
reprogramming efficiency. 
In contrast, non-integrating vectors such as adenovirus and Sendai virus, direct protein 
delivery, episomal vectors, and synthetically modified mRNA do not integrate the host 
genome, which can decrease the risks associated with the DNA-based integrating methods. 
Sendai virus transduction, as a DNA free method, has very high efficiency, 0.1-1%, that is 
100-fold compared to standard methods and does not require multiple rounds of transfection 
which is required for some vectors [36], [37]. Sendai virus is an enveloped virus with a 
negative-sense single-stranded RNA. After infection, the virus goes through genome 
replication and protein synthesis in the host cytoplasm, and then daughter virus particles are 
assembled and released keeping the genome intact [36], [38]. Sendai virus vector is considered 
as a safe method for clinical studies of gene therapy for cystic fibrosis [39], [40] as well as gene 
vaccine delivery [41]. 
microRNAs mediated reprogramming has become more important recently. miRNAs are able 
to facilitate the reprogramming through the induction of reprogramming factors such as miR-
302 [30] or even induce the reprogramming on their own expression [42], [43]. It has been 
shown that overexpression of miR302/367 cluster is enough to reprogram mouse and human 
fibroblasts with high speed and efficiency without using conventional reprogramming factors. 
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Modified synthetic mRNAs encoding the reprogramming factors Oct4 (Pou5f1), Sox2, Klf4, 
and c-Myc have been shown to successfully generate iPSCs with high efficiency [44]. mRNA 
mediated reprogramming was performed in combination with B18R interferon inhibitor to 
avoid the innate antiviral responses. This suggests the faithful application of mRNA 
reprogramming in regenerative medicine and therapeutic stem cell clinical application. 
Another non-integrating method is using episomal vectors. Episomal vectors are considered as 
a safe method and suitable for clinical grade applications. Yamanaka reprogramming factors 
plus Nanog, Lin28, SV40 LT, as well as IRES2 a co-expression factor, have been introduced 
to vectors with the Epstein–Barr virus (EBV) origin [45]. This method was limited to using 
different cell types and low efficiency. In another study using p53 suppression and 
nontransforming L-Myc, the efficiency was significantly increased, and iPSCs were 
successfully derived from various donors [46]. A more recent study demonstrated higher 
efficiency in the episomal reprogramming of Oct4, Sox2, and Klf4 with no oncogene ectopic 
expression of c-Myc and Lin28 [47]. 
Direct protein delivery has also been reported as a safe method for iPSCs derivation [48]. Oct4, 
Sox2, Klf4, and c-Myc recombinant proteins were fused with a cell-penetrating peptide (CPP) 
and used as reprogramming factors to treat somatic cells. Protein-induced iPSC method was 
very slow and lacked high efficiency; however, this method excluded the risk of using any 
DNA and vectors. Application of small molecules has also been considered as a promoting 
factor in some reprogramming methods. In a protein-induced method, reprogramming proteins 
generated iPSCs in the presence of valproic acid (VPA), a small-molecule HDAC inhibitor 
[49], [50]. It has been shown that reprogramming is doable without the oncogenes Klf4 and 
c-Myc if VPA is applied during the retrovirus reprogramming process [51]. 
It is now routine in many laboratories to use non integrating methods such as Sendai virus or 
plasmids for reprogramming. Although all integration-free methods are prominent for iPSC 
application in the clinic, it should be noted that optimisation is required before being applied 
in clinical trials. 
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2.2 XENO-FREE FEEDER-FREE IPSC CULTURE COATING 
Cultivation of induced pluripotent stem cells is as crucial as reprogramming. Correct 
cultivation supports full reprogramming and maintains the stem cell pluripotency and 
homogeneity at a high level and prevents differentiation. Culture conditions can change the 
gene expression profile and influence the stem cell characteristics and further downstream 
applications. To provide an efficient cellular model, it is essential to optimise and standardise 
the iPSCs culture condition. One fundamental factor is an effective coating system as stem cells 
widely interact with each other and the extracellular matrix. 
Initially, human pluripotent stem cells were cultured on feeder layers obtained from inactivated 
mouse embryonic fibroblasts (MEFs) [3], [7]. Later, inactivated human foreskin fibroblasts 
(HFFs) have also been used as feeder layers for expanding pluripotent stem cell lines 
accordingly [52]. Using the mouse and human feeder layers both raise the concern of 
contamination as well as the presence of non-human and unmatched immunogenic epitopes 
which impede the clinical applications of pluripotent stem cells. Therefore, feeder-free cultures 
were considered as an alternative method. The first used substrate was Matrigel; a basement 
membrane extracted from mouse Engelbreth-Holm-Swarm (EHS) tumour that consists of 
certain macromolecules; mainly type IV collagen, laminin, the heparan sulfate proteoglycan, 
and entactin [53], [54]. Matrigel supports stem cell growth while cells maintain stem cell 
characteristics similar to feeder layer including self-renewal maintenance, pluripotent gene 
expression, and teratoma formation ability. Later on, several extracellular matrix proteins such 
as Vitronectin, laminin-521, E-cadherin, and Fibronectin have been used as a feeder-free 
culture. Besides the sizeable batch-to-batch matrigel variability, these substrates are of 
xenogeneic origin [55]; therefore a suitable and xeno-free culture is still required to be able to 
use the pluripotent stem cells for pharmaceutical and regenerative medicine applications. 
Recently the focus has been on developing synthetic based substrates like peptide and polymer-
based substrates, and hydrogels. Furthermore, a host adaptable system as well as a three 
dimensional (3D) scaffold with the aim of imitating the in vivo environment, have been 
considered for iPSC applications. 
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Neuroepithelial stem cells (NESCs) in monolayer culture 
(Self-organisation of NESCs into rosette structures) 
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3 HOW TO MIMIC THE IN VIVO SITUATION TO CAPTURE 
DISEASE-RELATED PHENOTYPES  
To establish a good cellular model and recapitulate the disease-related phenotypes, it is 
important to understand the disease hallmarks and its pathophysiology in order to focus on 
generating relevant cells that are associated with the disease. Studying the endpoint samples of 
diseases are not very helpful because the disease has already been developed. Moreover, this 
does not help us to understand the development, onset, and the progression of the disease which 
might be more crucial. It is believed that causal genes for neurodevelopmental disorders take 
effect during the early embryonic stage of fetal development. Regarding neurodegenerative 
diseases, even if the onset of the diseases appears in adulthood, the phenotypic differences can 
be present in early neural development. In addition, transcriptome profile and functionality 
assays revealed that the in vitro derived iPSC neurons are immature neurons and equivalent to 
fetal neurons. This unique similarity allows us to use them to study neurodegenerative disorders 
as well as neurodevelopmental disorders during neural development [56], [57]. Therefore, I 
believe that neural progenitor cells, which represent an early stage in the neural tube during 
development, are a good candidate for in vitro studies of neurological disorders. 
In 1982, Brent A. Reynolds and Samuel Weiss for the first time isolated neural stem cells from 
the striatum of the adult mouse brain and cultured them as monolayer and spheres. Isolated 
cells were Nestin positive and proliferated in the presence of EGF and were capable of 
differentiation to CNS neurons and astrocytes [58]. Later on, it was shown that isolated 
progenitors from adult mouse striatal tissue were multipotent and characteristic of stem cells. 
Neural stem cells were cultivated in the presence of bFGF [59]. The neural progenitors/stem 
cells have been isolated from many regions of the human brain such as SVZ [60], SEZ and 
hippocampus [61], and cortex [62]. By isolating neural stem cells from various parts of the 
brain, attempts were focused on in vitro neural induction from ESCs and later iPSCs. Initially, 
induction protocols were performed by spontaneously differentiating EBs or using stromal 
feeder [63], [64]. However, none of these protocols was defined. 
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In vitro derivation of the neural stem cells is contingent with the understanding of in vivo 
processes. The nervous system initially develops from the neural plate from the embryonic 
ectoderm in the 3rd week after fertilisation. The neural plate is induced by a number of 
coinciding signals including BMPs, FGF, Shh, and Wnts which all interact synergically in a 
spatial and temporal manner leading to neural induction. BMP signalling is one of the key 
regulators of ectoderm transformation that controls the cell fate decision, proliferation, and 
patterning. BMP proteins, belonging to transforming growth factor-β (TGF-β) protein 
family, bind to the BMP receptors and trigger the signal via activation of Smad proteins. This 
signal results in translocation of activated Smad complexes to the nucleus to regulate the 
expression of the target gene with the help of other nuclear cofactors. The BMP antagonists, 
such as Noggin, I-Smads, and Chordin, can block the BMP signal allowing the ectoderm to 
procure the neural fate. Active suppression of BMP signalling is known to be a general 
mechanism for neural induction [65]–[67]. 
Based on in vivo neural induction, Lorenz Studer’s laboratory reported a dual-SMAD-
inhibition protocol as an efficient in vitro derivation of neural stem cells from hESCs and 
hiPSCs [68]. Simultaneous application of Noggin and SB431542, two inhibitors of SMAD 
signalling, increases the neural induction efficiency and yields a higher number of neural stem 
cells in comparison to conventional EBs formation or stromal feeder-mediated induction 
methods. 
Recent studies on hESCs and hiPSCs have shown the derivation of stable neural progenitor 
cell lines as an expandable intermediate cell population to study early stages of development 
[69], [70]. The capture of these progenitors is quick, efficient, and reproducible, while the cells 
maintain neural progenitor/stem cell characteristics. The rosette-forming cells isolated from 
neurally induced pluripotent stem cells are propagated in serum-free medium supplemented 
with bFGF and EGF while retaining a high self-renewal capacity, as well as high neurogenic 
potential upon differentiation. These cells, named long-term self-renewing neuroepithelial-like 
stem cells: lt-NES cells hereafter called NESCs. NESCs are expandable for 100 or more 
passages without losing their neurogenic potential. NESCs express neural precursor markers 
Nestin and SOX2, as well as neural progenitor cell markers SOX1 and PAX6. Derived NESCs 
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are also positive for rosette marker transcription factors PLZF and DACH1, as well as a polarity 
marker of neuroepithelial cells ZO-1 which is expressed apically and indicates the polarised 
organisation of NESCs in culture [71]. Different types of neuronal subtypes can be acquired 
from NESCs by either bFGF and EGF removal or more specifically, applying extrinsic factors 
inspired from in vivo development; forebrain cholinergic neurons [72] and midbrain 
dopaminergic neurons (mDAn) [73]. It has been shown that NESCs are developmentally 
similar to neuroepithelial stem cells captured from the human fetal brain [74]. NESCs have 
been considered as a worthwhile tool for in vitro disease modelling [75]–[77] as well as the 
potential for use in high-throughput screening applications (HTS) [78]. A very recent study 
also showed the potential of NESCs to make functional astrocytes ‘‘NES-Astro’’ in a defined 
condition [79]. 
In the next 2 sections, I will describe examples of neurological brain disorders where cellular 
models have been used to uncover disease mechanisms; Alzheimer’s Disease as a 
neurodegenerative disorder and Type 1 Lissencephaly as a neurodevelopmental disorder. 
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4 ALZHEIMER’S DISEASE 
Alzheimer’s disease is the most common form of dementia that affects millions of people 
around the world. According to the World Health Organization (WHO), approximately 35 
million people around the world are suffering from AD. The rate of disease is rising quickly 
while there is no promising prevention, neither effective treatment. The disease gives a 
progressive neurodegeneration of the brain, where the forebrain cholinergic neurons are 
affected early in the disease process and results for example in impaired memory. The 
neurodegeneration can correlate with the two major neuropathological features of AD, the 
presence of large numbers of extracellular senile (neuritic) plaques and neurofibrillary tangles. 
Amyloid plaques comprise of the amyloid beta peptide (A) aggregates, surrounded by 
dystrophic neurites and glial cells. Neurofibrillary tangles are abnormal intraneuronal proteins 
organised in bundles of paired helical filaments, composed of hyperphosphorylated forms of 
the microtubule-associated protein Tau [80], [81]. The disease is multifactorial, and it is 
estimated more than one hundred genes are involved. AD is categorised into two types, late 
onset and early onset. The late onset of AD is the most common form and occurs after age 65. 
There is no defined mutation or any single cause leading to the disease; however, ApoE 
polymorphism (4) has been recognised as a significant risk factor [82]. This type is called 
sporadic AD. In contrast, familial AD is rare, runs in families and ordinarily has early-onset, 
usually under age 60 [83]. It has been established that mutations in genes responsible for A 
peptide production (amyloid precursor protein (APP), and two components of the -secretase 
enzyme; presenilin1 (PS1) and presenilin2 (PS2)) lead to familial AD. A peptides consist of 
36 to 43 amino acids that are typically produced from APP by sequential cleavage of the 
enzymes -secretase and -secretase. One of the known mutations in APP is a point mutation 
in exon 17 on chromosome 21 that replaces a Val → Ile, known as London mutation 
(Val717Ile) [84]. A monomer is the normal form of the protein. However, in the disease 
process, these peptides can form oligomers and insoluble aggregates that are one of the 
pathological hallmarks of the disease [83], [85]. 
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Despite the fact that AD is ordinarily human-related and knowing animal models are not 
capable to fully recapitulate human brain diseases, several cellular and animal models have 
been used to uncover AD mechanisms and discover potential treatments [86]. For example, a 
transgenic mouse model with APP mutation (V717F) showed the presence of amyloid plaques 
extracellularly in the mouse brain, but not neurofibrillary tangles. The Aβ accumulation 
associated with distorted neurites, synaptic loss, as well as dendrite reduction in the AD mouse 
hippocampus [87]. Another transgenic mouse model reported that Tau reduction did not 
influence the Aβ associated pathology, but instead prevented the cognitive deficits in AD mice. 
This result suggests that decreasing endogenous Tau protein could be a potential treatment for 
the disease [88]. 
Recent studies have shown that it is possible to model the disease in vitro and capture different 
aspects of the disease despite the fact that in vivo symptoms do not appear until later in life. 
The first iPSC-based model of AD reported increased Aβ42 secretion in neurons derived from 
familial AD patients carrying PS1 or PS2 mutations. This model demonstrated the 
recapitulation of the disease-related pathology in a dish. The elevated Aβ 42/40 ratio was 
rescued with γ-secretase inhibitor treatment [22]. In another study, iPSC-derived neurons from 
two familial AD patients with APP duplication and two sporadic AD patients showed an 
increase in Aβ40 secretion, phosphorylated Tau, and aGSK-3b. Treatment with β-secretase 
inhibitor could rescue the elevated phosphorylated Tau protein and aGSK-3b, but not Aβ40 
[23]. 
More specifically, cholinergic iPSC derived neurons from sporadic AD patients with 
ApoE3/E4 genotypes, represented AD pathology including increased Aβ42/Aβ40 ratio and 
response to γ-secretase inhibitor treatment [89]. Derived neurons were more susceptible to 
increased glutamate toxicity and cell death. Forebrain neurons derived from familial AD 
patients with the London mutation showed significantly elevated Aβ, Aβ42/40 ratio, and Tau 
protein levels compared to control neurons [90]. The total and phosphorylated Tau protein 
levels could be rescued via Aβ depletion.  Specific monoclonal and polyclonal anti-Aβ 
antibodies treatment sequestered the Aβs and decreased the total Tau protein level only at the 
early stage of differentiation. 
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To recapitulate more aspects of this complex disease and uncover the mechanisms, recent focus 
has been on developing more enhanced in vivo related models such as 3D neurosphere culture 
and brain organoid culture systems. Tau neurofibrillary tangles, one of the AD hallmarks, was 
recapitulated for the first time in the 3D culture of a genetically engineered human NSC line 
overexpressing several familial AD-associated genes [91], [92]. A recent study reported the 
presence of Aβ and Tau protein aggregates in neurosphere culture from engineered human NSC 
and iPSC lines with familial AD [93]. 
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5 LISSENCEPHALY 
Lissencephaly is a neuronal migration disorder that is considered to have a neurodevelopmental 
cause. In the developing brain between 5 and 22 weeks of gestation, immature neurons derived 
from neural stem cells in the ventricular zone migrate over hundreds of cell body distance from 
their sites of origin toward the cortical plate in an inside-out manner to build the six cortex 
layers. Mutations in several genes such as LIS1 (PAFAH1B1), DCX, and TUBA1A are 
involved in neuronal migration leading to lissencephaly [94]. Lissencephaly (smooth brain) 
explains a range of brain malformations characterised by a smooth cerebral surface, resulting 
in developmental delay, many neurological disabilities, and seizures. Mutated cells fail to 
migrate correctly from the ventricular zone to the cortex during brain development, resulting 
in the development of a poorly organised cortex without regular folds and ridges. Based on 
disease pathogenesis Lissencephaly is classified into two classes; the classical Lissencephaly 
(Type 1 Lissencephaly) and subcortical band heterotopia (SBH). Patients with Type I 
Lissencephaly carry a mutation in one of the migratory related genes resulting in the 
development of a thickened cortex with absent (agyria) or reduced folding. In contrast, SBH 
patients develop a grey heterotopic band beneath the cortex located in the central white matter 
(Figure 1). SBH often occurs in females and presents with less severe malformation compared 
to the classical Lissencephaly affected patients [95].  
 
 
Figure 1 T1-weighted magnetic resonance images of a healthy brain compared with two Lissencephaly patient brains. (a) 
A healthy brain; (b) Classical Lissencephaly with a mutation in DCX gene (c) SBH in a female child with a mutation in 
DCX gene, the arrow indicates the subcortical band. Picture adapted from reference [96]. 
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LIS1 is the first discovered gene that causes Lissencephaly associated with Miller-Dieker 
Lissencephaly syndrome [97]. The gene is located on chromosome 17 and encodes the platelet-
activating factor acetylhydrolase (PAFAH1B1). LIS1 plays roles in a variety of biological 
processes such as functioning as a regulatory protein activator factor, involvement in neuronal 
migration, and axon growth. LIS1 interacts with DCX and the microtubule motor cytoplasmic 
dynein to regulate microtubule dynamics, in addition to cell division [98], [99]. 
TUBA1A gene located on chromosome 12 belongs to the tubulin superfamily. The gene 
corresponds to tubulin alpha 1a protein which is abundant in the developing brain and is a main 
component of microtubules. TUBA1A is essential for proper microtubules function which 
explains its involvement in cell motility and neuronal migration [100]. 
Doublecortin is the major causative gene of X-linked Lissencephaly. Males with hemizygous 
DCX mutations result in the classical form of Lissencephaly (Type 1 Lissencephaly) which 
shows a severe phenotype (Figure 1b). Females with heterozygous DCX mutations represent 
SBH Lissencephaly with a genetic mosaicism. Due to random X-inactivation, two populations 
of migrating neurons are produced. One population expresses the normal DCX allele and 
migrates correctly to establish the outer cortex. The other, with the mutated DCX allele, fails 
to adequately migrate resulting in the formation of the heterotopic band of neurons (Figure 1c) 
[101]. The gene encodes the brain-specific microtubule-associated protein consisting of 360 
amino acids with a 40 kDa predicted protein [102], [103]. DCX is expressed in neural 
progenitors and immature neurons and is abundant in the cell soma as well as tips of neurites. 
DCX acts in the migration of neural stem cells from the ventricular zone to their final 
anatomical destinations to build up the six layers of the cortex. DCX expression is regulated 
during brain development [104] and so far has been used widely as a neurogenesis marker. The 
expression is sustained in migratory neuroblasts as well as adult neurogenesis regions, the 
dentate gyrus and the lateral ventricle wall/olfactory bulb axis [105].  
DCX function and involvement in every step of neuronal migration is currently poorly 
understood. DCX localisation was demonstrated for the first time by Gleeson in 1999 
suggesting a distinct expression in the periphery of the cell soma surrounding the nucleus and 
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expanding to the proximal neurite [104]. DCX co-localises with microtubule compounds such 
as actin suggesting its association with microtubule cytoskeleton through stabilising the 
microtubules. Most likely, DCX does not support microtubule growth, but instead prevents de-
polymerisation and thus functions as an anti-catastrophic factor [106]. DCX binds directly to 
tubulin dimers or microtubules through the two tubulin-binding domains (N-DC and C-DC) 
which are evolutionarily conserved tandem repeat domains. Mutations in the DCX gene in 
Lissencephaly patients are mostly identified as single-amino-acid substitutions within this 
domain region [101]. It has been shown that DCX microtubule interaction is modulated through 
DCX phosphorylation in the axonal wrist [107]. Phosphorylation of DCX by Cdk5 results in a 
free DCX whereas the dephosphorylated form of DCX by spinophilin accompanied with pp1 
increases the affinity to the microtubule and leads to binding and stabilisation of the 
microtubule and promoting its polymerisation. DCX also interacts with dynein and LIS1 to 
mediate nucleus-centrosome coupling during migration [108]. 
Besides two microtubule binding sites, DCX consists of a Ser/Pro-rich C-terminal domain 
which is not required for microtubule binding [109]. This domain gives DCX a phosphoprotein 
characteristic containing multiple phosphorylation sites that interact with clathrin-associated 
proteins and several protein kinases such as the JNK, PKA, and Cdk5. Apart from the 
established role of DCX in microtubule dynamics, it has been suggested that DCX could play 
a role in vesicle trafficking via the cell adhesion molecule neurofascin. Independent of 
microtubule binding, DCX functions as an endocytic co-adaptor to modulate the neurofascin 
localisation on the plasma membrane and increase the endocytosis in neuronal culture [110]. 
This regulation besides other involved adaptors and molecules in endocytic membrane traffic 
is proposed to be crucial for neuronal migration guidance and therefore important in the 
development of the nervous system [111]. 
Previous studies investigating the role of DCX particularly in Lissencephaly have been 
performed in animal models as well as primary cell lines. The first Dcx knock-out animal model 
study showed remarkably normal overall brain morphology in Dcx mutant mice. The 
hippocampus showed disrupted lamination resulting in learning deficits despite the normal 
patterns of neocortical neurogenesis and neuronal migration [112]. This observation was later 
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shown to be due to the doublecortin-like proteins compensatory mechanism in mice [113], 
[114]. In contrast, a rat model using in-utero RNAi method demonstrated the development of 
an SBH like phenotype showing radial migration defects in some neuronal progenitor cells in 
rat neocortex. These contrasting results presented a more complicated role of DCX than current 
information suggests [115]. 
More recent studies have suggested that DCX is possibly involved in cell proliferation. 
Forebrain human neural progenitors derived from H9 hESC line were transfected with binary 
piggyBac transposons and then migration was followed on matrigel substrate and brain slice 
cultures. It was shown that ectopic expression of DCX in the forebrain human neural 
progenitors inhibited neural progenitor proliferation and promoted migration [116]. 
Animal models from recent literature theorise that double cortex formation is not only 
derived by neuroblast migratory defects. A GTPase RhoA mutant in the dorsal telencephalon 
of mice exhibited radial glial scaffold defects leading to a double cortex-like phenotype. 
Depletion of RhoA caused disruptions in the radial glial scaffold with loss of adherens 
junction anchoring and defects in the maintenance or formation of radial processes [117]. 
Another study suggested a different mechanism of double cortex formation. A mutation in 
adhesion molecules afadin or CDH2 in the dorsal telencephalon of mice drastically increased 
cell proliferation of progenitors that led to double cortex like phenotype. Disruption of 
essential adhesion junction proteins for radial glial cells significantly affected the neocortex 
development through altering progenitor proliferation along with abnormal axonal 
projections. Radial glia disruption affected cell positioning, alters progenitor proliferation, 
and perturbs neocortical cell layers [118]. 
Along with DCX, additional mechanisms have been described for guiding the migrating 
neurons and neurites to their targets in the brain, including the Slit/Robo signalling [119]. 
Slit ligands are multifunctional proteins that act importantly in a variety of developmental 
processes such as neurogenesis and angiogenesis [120]. One well-studied function of Slit 
proteins is during the development of the nervous system. Slit proteins have been shown to 
bind to Robo receptors and bifunctionally regulate neuronal migration and axon guidance. 
The chemorepulsive action of Slit proteins functioned in the regulation of migrating cells, 
axon guidance, and axon branching [119].  
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6 KEY ASPECTS OF CHOOSING AN APPROPRIATE 
CELLULAR MODEL OF THE BRAIN 
Several points appear to be controversial in defining a perfect cellular model. It is complex to 
choose a proper model that can feasibly translate results to humans and apply in clinical 
features. The history of the disease being studied such as heritability, sporadic or familial, or 
multifactorial, can influence results and make the identification of the mechanism more 
difficult. In the case of multifactorial diseases, large population size may help to produce more 
reliable data and avoid false results. 
To derive a cellular model, the primary focus is on the derivation of standardised, robust, and 
reproducible iPSCs. How and when an iPSC line is considered a perfect line, how to decrease 
the heterogeneity of derived iPSC lines, and to what extent are iPSCs identical to hESCs, are 
still questioned. It has yet to be determined whether it is enough to show that iPSCs are 
similar in morphology, gene profile, and in vivo/in vitro differentiation capability. 
Alternatively, if each iPSC line should be evaluated in vivo and assess the responses to 
intrinsic signals, and observe if and how responsive they are to in vivo host developmental 
cues. To understand this better, complementary methods such as parallel experiments with 
hESCs or generating isogenic controls to endorse the iPSC-based model findings are 
required. More optimisation is required to avoid partial reprogramming and eliminate those 
cells which have been partially reprogrammed. Additional systematic assays might be 
required to thoroughly examine the iPSC differentiation potential and later on, the 
functionality of the differentiating cells. Is it enough to use developmental cues and generate 
the desired cell types, or go through the integration to the host system to evaluate the 
functionality? The in vitro link between gene expression and functionality, as well as survival 
and integration of derived cells to the host, remain to be shown. An important question which 
arises is the best way to acquire mature neurons; this might be possible with long-term culture 
or accelerating the differentiation by environmental factors. Perhaps multifactorial 3D 
platforms such as neurospheres, organoids, and microfluidic systems could provide a better 
environment that mimics the in vivo condition. 3D cultures have made notable improvements 
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in the field so far, and many disease features that had not been identified in monolayer 
cultures are on the way to recapitulation. 
The epigenetic memory is a highly concerned issue. iPSCs possess specific features resulting 
from reprogramming itself or remaining from the original somatic cells. These newly 
acquired cell properties can cause complications in iPSC clinical applications. Direct 
reprogramming, transdifferentiation, of somatic cells to desired differentiated cell types 
could offer a better solution to make patient-specific cell models since the stem cell stage is 
skipped and they undergo a shorter reprogramming process. These cells may 
retain epigenetic signatures related to age which could provide more suitable cells to study 
neurodegenerative disease mechanisms. 
To accurately reach the main goal of iPSCs for clinical application, matters discussed above 
must be carefully considered. Stochastic events during reprogramming and differentiation, 
epigenetic memory, genomic de novo mutations, prolonged cultivation of derived cells, and 
cell maturity, can result in significant concerns for clinical application even if this is an 
autologous based therapy. 
 
There is still much to be done, even so, research is moving in the right direction to answer 
the questions of what is the best cellular model and how best to utilise the technique. 
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7 AIMS OF THE THESIS  
 
The main goal of this doctoral thesis was to study neurological disorders and explore novel 
mechanisms underlying the diseases. To achieve my general goal a proper relevant cellular 
model was required which led me to specifically set my subgoals: 
1. Derivation and establishment of human iPSC lines from healthy and diseased 
individuals in standardised conditions. 
2. Derivation and establishment of robust, reproducible and well-defined neural 
progenitor populations from the healthy and patient derived-iPSC lines. 
3. Identification of known disease-relevant phenotypes of Alzheimer’s disease and  
Type 1 Lissencephaly as well as discover novel mechanisms underlying the diseases in 
2D and 3D  models. 
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8 RESULTS AND DISCUSSION 
8.1 GENERATING HEALTHY AND PATIENT-SPECIFIC IPSC LINES  
The first step to build an in vitro model was establishing induced pluripotent stem cells. We 
have reprogrammed patient and healthy fibroblasts at early passage by introducing Yamanaka 
factors Oct4, Sox2, Klf4, and c-Myc using non-integrating Sendai virus vectors as an efficient 
and reproducible system (Figure 2A-K). Transduced cells with SeV vectors displayed the 
mesenchymal to epithelial transition morphological changes from second-day post-
transduction (Figure 2E). ES-like iPSC colonies were visible after 10 days. Colonies were 
picked manually and transferred onto irradiated human fibroblasts approximately 3 weeks post-
transduction. Derived iPSCs possessed stem cell characteristics equivalent to hESCs including 
similar cell morphology with a large nucleus and a small cytoplasm. The colonies arose with 
distinct sharp edges. After reprogramming, SeV particles were gradually diluted out by 
passaging of iPSCs where they disappeared, usually by passage 10. Immunofluorescence 
staining confirmed expression of pluripotent stem cell markers including cell surface markers 
TRA1-60 and TRA1-81 and pluripotent cell nuclei markers Oct4 and Nanog. To validate the 
pluripotency of derived iPSC lines we chose PluriTest. iPSCs transcriptome data of an Illumina 
Gene Expression HT12 Direct Hybridization assay were evaluated online by uploading to the 
PluriTest web-portal (www.pluritest.org). The iPSC lines used in all papers have passed the 
PluriTest with low novelty indicating high pluripotency of the derived iPSC lines. Derived lines 
have been karyotyped with the G-banding method and showed normal 46 karyotypes. 
Together, all data show that the derived iPSC lines from patient and control expressed 
pluripotent markers and were capable of differentiating into three different germ layers while 
having a normal karyotype and maintaining their proliferative trait in the culture without 
differentiating. We have not detected any differences in the characterisation of derived lines. 
The data suggested that we had true iPSC lines that behaved similarly regardless of different 
genetic backgrounds, which allowed us to use them for the downstream aims. 
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In paper I we have shown an example of how to optimise the culture condition. Derived iPSC 
lines have been cultured further using recombinant spider silk, 4RepCT matrices, as a defined 
feeder-free system. The bio-inspired polymers from spider silk can be produced in a 
recombinant manner in several variants fused with known cell binding peptides from matrix 
proteins. The recombinant miniature spider silk protein 4RepCT fused with vitronectin is 
processed into 2D film or 3D foam and fibre structures. Cultivation of the healthy iPSC lines 
(Ctrl 3 and Ctrl 5) and hESC lines (H9, HS360, and HS181) on 4RepCT film possessed the 
typical stem cell morphology. Immunofluorescence analysis showed the expression of stem 
cell nuclei markers Oct4 and Nanog, and cell surface markers SSEA-4, TRA1-60, and 
TRA1-81 by flow cytometry analysis. Taken together, we have shown that the recombinant 
miniature spider silk can provide a xeno-free culture supporting pluripotent stem cell growth 
comparable to matrigel along with forming a 3D matrix and compatibility with the host 
immune system. Besides providing a suitable xeno-free culture coating for iPSCs, spider silk 
protein is biodegradable after implantation [121]. Spider silk protein can also be modified to 
hold recombinant proteins such as growth factors like FGF2, possibly providing a more stable 
and consistent way to present such factors to the cells. This can provide an optimal routine 
culture system for pluripotent stem cells and future iPSC based therapies. 
Based on recent studies using laminin as a feeder-free coating [122], [123], we have evaluated 
recombinant laminin-521 for iPSC line culture and found that it is also a biologically relevant 
feeder-free xeno-free substrate that is suitable for stem cell culture [124]. 
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Figure 2. Derivation of hiPSCs. (A-C) Patient and healthy fibroblasts are established from a skin biopsy. (D) 
Fibroblasts at a low passage with 70-80% confluency are induced with Yamanaka factors. Morphological 
changes are seen in transfected cells 2 (E) and 6 (F) days post-transduction. (G-I) Emerged iPSC colony one 
(G), two (H) and three (I) weeks post-transduction (J) Colonies are manually picked and transferred to 
inactivated HFFs. (K) A typical iPSC colony on inactivated HFFs.  
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8.2 GENERATING WELL-DEFINED NEURAL PROGENITOR POPULATIONS 
FOR IN VITRO STUDIES OF NEUROLOGICAL DISORDERS 
Direct differentiation of ESCs and iPSCs to the desired neurons has generally been a long 
process resulting in a heterogeneous neuronal population consisting of unwanted cell types. 
We sought to generate intermediate expandable NESC lines from patients and healthy 
undiagnosed individuals. All NESC lines in the study have been generated in the lab based on 
protocols we have derived and modified in Paper III and [70] (Figure 3). Morphologically, 
the derived NESCs self-organised into rosette structures with a mermaid shape that grew head 
to head. They expressed neural precursor markers Nestin and SOX2, SOX1 and PAX6. 
Derived NESCs were also positive for rosette marker transcription factors PLZF and DACH1 
as well as the polarity marker of neuroepithelial ZO-1. In paper III transcriptome data analysis 
of different NESC lines from two Lissencephaly patients and two controls represented high 
similarity between lines. Hierarchical clustering showed the NESCs clustered together separate 
from the differentiating cells. The expression of general neural progenitor markers of the DCX 
mutant and control derived NESC lines such as Nestin, SOX2, SOX1, PLZF, DACH1, PAX6, 
HES5, and MMNR1 did not differ at NESC stage. This transcriptional similarity proposed the 
homogeneity of our NESC population despite patient genomic background variation. 
Our data showed that we have successfully established a robust system to generate a stable 
neural progenitor population that represented the in vivo early neural stem cell characteristics, 
which made them a suitable system for modelling early human neurological development in 
health and disease. 
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Figure 3. Generating a stable NESC line. (A) 60-70% confluent iPSC culture is neurally induced in the presence 
of LIF and chemically defined factors including CHIR, SB431542, and DAPT for 5 to 7 days. (B, C) 
Neuralisation is observed after 5 days. (D) Neural rosettes are picked manually and cultured in suspension for 
48 hours. After two days, neurospheres are dissociated and (E) Single cells are plated on  
a poly-L-ornithine/laminin-coated plate in NESC medium. 
  
Neuralisation 
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8.3 AN APPROPRIATE CELLULAR MODEL MIMICS THE DISEASE KNOWN 
RELATED PHENOTYPE 
8.3.1 AD model 
In paper II we have modelled Alzheimer’s disease (AD) with a healthy derived NESC line to 
explore the disease-related phenotype in the dish. NESCs have successfully been differentiated 
to cholinergic neuronal subtypes on 2D and further subcultured on 3D (SAP: self-assembling 
peptide matrix) with the sequential application of extrinsic factors Shh, BMP9, and NGF which 
supports cholinergic neurons in the forebrain. First, we assessed the effect of two culture 
conditions on expression patterns of some AD-associated proteins including pPAK, Cofilin, 
and Drebrin in differentiated cells. Quantitative immunofluorescence analysis revealed 
significant differences between 2D and 3D cultivation, which suggested that neurons in 3D 
culture more closely mimicked the in vivo situation compared to a conventional 2D culture. 
Both 2D and 3D cultures were then treated with beta-amyloid (Aβ) oligomers to mimic the AD 
pathology in the dish. Interestingly, the disease-related phenotypes, reduction of pPAK and 
Drebrin protein levels, could only be recapitulated in 3D culture and not in standard 2D culture 
when treated with Aβ oligomers. Our data has shown that Aβ oligomers in 3D culture affected 
the subcellular localisation of pPAK and Drebrin proteins from cytosolic and nucleus regions 
to sub-membranous regions, which have also been seen in vivo in post-mortem Alzheimer’s 
brains [125]. P21-activated kinase proteins (PAKs) are involved in brain diseases, particularly 
AD, functioning on neuronal morphology as well as forebrain development [126]. It has been 
reported that the PAKs and Drebrin levels are reduced in AD patient brains, at the protein level 
and even more so on the activated protein levels; pPAK. This finding is in accordance with 
animal models and AD patient brains. These results show the unique potential of NESCs 
cultured in 3D to faithfully model human disease and being a suitable tool for in vitro disease 
modelling. 
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8.3.2 Type 1 Lissencephaly model 
In paper III we studied Lissencephaly using iPSC-derived neuroepithelial stem cells from two 
patients carrying Type 1 Lissencephaly. The first patient (DCX-R19Stop) carries a nonsense 
mutation (c.C55T, p.Arg19ATOP) and the second patient (DCX-T88M) a missense mutation 
(c.C263T, pThr88Met), both male. To derive disease-relevant cell types, we have 
reprogrammed fibroblast cells from patients and two samples from healthy persons using SeV. 
Characterized iPSC lines were neurally induced to generate NESCs. Derived patients NESCs 
did not indicate any phenotype differences regarding the expression of neural stem cell markers 
as well as proliferation rate. 
 
8.3.2.1 Patient cells exhibited different DCX expression patterns compared to control cells 
upon differentiation 
To reveal the DCX expression profile, NESC lines were differentiated spontaneously to 
neurons by removing growth factors EGF and bFGF from the medium for 21 days. 
Immunofluorescence analysis indicated that mutant and control NESCs at proliferative stage 
did not express any DCX, whereas, upon differentiation, the expression was massively 
upregulated only in control cells, both on the RNA and protein levels. In contrast,  
DCX-R19Stop cells did not show any detectable DCX protein expression in differentiating 
neuroblasts and DCX-T88M cells expressed a slight amount of protein with more localization 
at the soma. DCX-R19Stop was derived from a patient with a premature stop codon at amino 
acid position 19 at the beginning of the protein while DCX-T88M has an amino acid 
substitution at position 88, which is in one of the microtubule binding domains. This could be 
an explanation why DCX protein is not detectable in DCX-R19Stop. 
Transcriptome data analysis of NESCs and differentiating cells from patients and controls 
revealed the effect of the DCX expression patterns. Hierarchical cluster diagram of 
transcriptome data analysis revealed that at NESC stage when the DCX protein is not 
expressed, NESCs from patients and controls clustered together separate from differentiating 
cells. Upon differentiation when DCX expression is upregulated, patient cells clustered 
together separate from control cells. This analysis indicated that deregulation of DCX in patient 
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cells directly affected the gene expression profile pattern and caused this clustering and 
separation. Based on the data we decided to look more closely only at diff control and diff 
patient cells (diff: differentiation day 7 to day21) increasing the statistical power. We have 
applied the p<0.05 cutoff and observed a large number of differentially expressed genes, being 
either up-regulated (4367) or down-regulated (2421) in patient differentiating cells. These huge 
transcriptional differences appeared to affect several phenomena such as migration and neurite 
outgrowth. 
 
8.3.2.2 DCX upregulation is connected with several phenomena during neuronal 
differentiation 
We have examined the neuronal migration capability of patient and control neuroblasts during 
differentiation. Results from clonal migration assay and time-lapse microscopy revealed a clear 
migration phenotype of mutated cells at both the pre-differentiated and differentiating stages; 
the methods are well-described in paper III. Time-lapse results of plated neurospheres over 
one-week pre-differentiation indicated less migration in DCX mutant compared to control. 
Furthermore, results from the clonal migration assay over a longer time of three weeks 
differentiation displayed a significant difference in patient and control cells. Again, DCX 
mutant cells migrated less and seemed to prefer to stay in the plating site rather than migrating. 
With this, we provided evidence to support the fact that Lissencephaly is considered as a 
migrational disorder. 
Additionally, we have observed fewer and thinner dendrite bundles, stained with neuronal 
marker MAP2, in differentiating neuronal culture in patient cells compared to control. We have 
also looked at neurite extension; the first stage which takes place in migrating neurons followed 
by translocation of the nucleus and cytoplasmic components [127]. Cells in the pre-
differentiation stage were dissociated and cultured in suspension for 24 hours to form 
neurospheres. Neurospheres were selected and embedded into matrigel on a cover glass. 
Emerged neurite length of differentiating neurospheres of patient and control samples were 
measured the following day using ImageJ. A shorter neurite length was observed in both patient 
lines. It has been reported that DCX is involved in neurite outgrowth through the JNK pathway 
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[127], [128]. JNK phosphorylates the DCX and stimulates neurite outgrowth. The shorter 
neurite length in patient cells might be a result of the defect in phosphorylation of DCX by 
JNK, which infers that the part of the protein fulfilling a function in neurite outgrowth is either 
not existing or not properly functioning in mutated cells. 
Data from transcriptome analysis supported the observed phenotypes. Hierarchical clustering 
and PCA analysis both indicated that patient cells cluster together away from control cells 
based on differentiation status. Interestingly, we identified miss-regulation of genes that are 
involved in cell migration, neurite outgrowth, and synapse maturation such as NTNG1, CHL1, 
and PPP1R9A which was consistent with the observed phenotype. We remarked some of the 
top scoring genes such as RELN, CNTN1, GABRR1, and FABP7 are disease-associated and 
have been reported in human brain disorders [129], [130], [131], [132]. Presence of cadherin 
superfamily members among differentially expressed genes suggested a probable defect in 
crosstalk between cell-cell adhesions and that could be one of the causes of defective migration. 
We continued with GO analysis and found out the involvement of highly relevant biological 
processes including neuronal differentiation, migration, axonal outgrowth and unexpectedly, 
cell proliferation. 
Our data is suggesting that the lack of a functional DCX protein can interfere with neurogenesis 
and lead to migrational defects, disrupt the neurite growth process, and fewer and thinner 
dendrite bundles in differentiating patient cells. This proposes an important role of DCX up-
regulation when progenitor neurons initiate differentiation and migration.  
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8.3.2.3 SLIT3 knockdown and treatment with recombinant Robo1/Robo2 proteins rescued 
the shorter neurites phenotype exhibited by Lissencephaly patients’ cells 
We have taken advantage of our transcriptome data and looked closely at the differentially 
expressed genes to investigate the possible cause of the observed phenotype of the shorter 
neurite length in patients’ neuroblasts. Based on literature and regarding the already known 
associated genes in migration and neurite outgrowth, we found that the gene SLIT3 was 
among the up-regulated genes in patient neuronal cells during differentiation. We attempted 
to generate SLIT3 knockdown NESC lines by using shRNA construct. Then performed 
neurite outgrowth assay with the SLIT3 knockdown patient and control NESC lines. SLIT3 
depletion rescued the detected phenotype; patients’ neurospheres from SLIT3 shRNA 
knockdown lines displayed significantly longer neurite length. 
In a parallel neurite outgrowth experiment, we applied the SLIT receptors to investigate 
whether the SLIT inhibition is mediating the neurite outgrowth extension. Data demonstrated 
that the exogenous application of Robo occupied the ligands preventing the SLIT3 protein 
from binding to the endogenous Robo receptors presented in neurospheres.  By this, neurite 
outgrowth of DCX-R19Stop and DCX-T88M was no longer suppressed. 
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8.3.2.4 Unexpected phenotype of Lissencephaly: DCX mutated cells exhibited a prolonged 
proliferation phenotype upon leaving NESC stage. 
Upon growth factor withdraw we have noticed patients NESCs remain proliferative. To 
evaluate the observed phenotype, we counted the number of cells as well as the number of Ki67 
positive cells during the differentiation window. NESCs were spontaneously differentiated in 
24 well plates by removing growth factors bFGF and EGF from the medium. Cells were 
counted every third day to follow the proliferation rate. Proliferation gradually ceased in 
healthy NESCs by growth factor removal; cells began to differentiate, become postmitotic, and 
proceeded into maturation. DCX-mutant cell counts were almost twice that of control cells 
following two weeks of differentiation. At the beginning of differentiation, more than 90% of 
patient and control cells stained positive for the proliferative marker Ki67. Upon 
differentiation, up to 70 % of control cells lost the Ki67 marker whereas DCX mutated cells 
maintained a higher percentage, 55% of the cells were still Ki67 positive. 
The patient neural stem cells seemed somewhat resistant to differentiation, suggesting that the 
lack of functional DCX protein in patient cells may have forced them to remain in the stem-
cell state, rather than to differentiate into new neuronal identities. Additionally, data from 
transcriptome analysis supported the observed phenotype. Genes connected to proliferation and 
cell adhesion remained upregulated in patient cells during differentiation compared to healthy 
cells. 
  
 36 
9 CONCLUSIONS AND FUTURE PERSPECTIVES 
The main goal of this doctoral thesis was to study neurological disorders and explore novel 
mechanisms underlying the diseases. As discussed in the beginning, it is difficult to study the 
early stage of human development in vivo for several reasons. Animal models have commonly 
been used as a research model to study human diseases, and although these animal models have 
contributed significantly to the research revealing valuable information, it is still challenging 
to extrapolate results obtained from animal experiments to humans. Therefore, in the absence 
of a comparable model organism, a suitable alternative human system is demanded. Regarding 
the ethical issues, a human cellular in vitro system could serve scientists as a prominent tool to 
study human disease mechanisms. iPSC technology has opened a new window in investigating 
underlying disease mechanisms and overcoming the above issues. iPSC technology allows 
scientists to rely on data from using in vitro models more safely. A consistent system in a 
standardised condition is essential to limit variations and obtain more reliable data that can be 
applied in the future for therapeutic applications and regenerative medicine. To identify brain 
disease-relevant mechanisms, it is crucial to be able to compare NESC derived neurons from 
genetically distinct pluripotent cells in a consistent manner. To do this, we need to produce a 
robust derivation and cultivation system from pluripotent cells to neurons, with high 
reproducibility that provides us with stable and comparable well-characterised cell lines. 
The results presented in paper I showed an example of standardisation of culture conditions. 
We showed that recombinant spider silk supported pluripotent stem cells growth while 
maintaining pluripotency as well as differentiation potential into three germ layers. 
Recombinant spider silk could be an example of an optimal routine xeno-free culture in both 
2D and 3D systems for pluripotent stem cells. 
After derivation and characterisation of iPSC lines, we then attempted generating NESCs. Here 
we have established a reliable in vitro method to generate and differentiate NESC lines from 
patient and healthy samples. We have shown that NESC populations derived from healthy and 
disease donors maintained a homogenous population, they showed similarity in gene 
expression profile despite their different genetic backgrounds.  
In paper II we used a control NESC line to model Alzheimer’s disease. We showed the 
potential of our healthy derived NESC line as a suitable tool to model AD and explore the 
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disease-related phenotype in the dish. Recapitulating AD-related phenotypes only in 3D 
neuronal culture suggested the importance of environmental context in cellular disease 
modelling. We proposed that 3D models which closely mimic the in vivo situation can be 
employed as more refined tools for studying brain development and disorders. 
Finally, we have used patient-specific derived NESCs to investigate Type 1 Lissencephaly 
phenotype in a dish. Data presented in paper III confirmed the known migratory deficit in 
patient DCX mutant neuroblasts. The migration defects combined with the apparent initial 
resistance of patient NESCs to differentiate and aberrant neurite outgrowth suggested a central 
role of DCX up-regulation when progenitor neurons initiate differentiation and later migration. 
Interestingly, our data revealed that the two different DCX mutations exhibited the same 
phenotypes. Based on literature research, this study is the first cellular model of Lissencephaly 
using patient DCX mutant iPSCs. 
Further investigation needs to be done to explore the exact role of DCX along with which 
cellular signals and/or downstream effectors that are terminating NESC proliferation and 
initiating differentiation and migration. Future work would involve being able to compare a 
homogeneous neuroblast cell population. Looking at different stages of differentiation to 
neurons would also be important in creating a robust method. One way would be to sort cells 
or use reporter constructs to obtain a more homogenous population. For example, using a 
fluorescent reporter under the control of the human DCX promoter to ensure the comparison 
of only DCX expressing cells from patient and control. Cell sorting would be an advantage 
when studying migration for instance, where we can track the same cell population. And 
finally, using the genome editing technology, the RNA‐guided nucleases (CRISPR/CAS9), to 
correct the mutation and attempt to rescue the phenotype which in turns offer a unique platform 
in future for personalised therapies and drug screening. 
This thesis underlines the importance of a cellular model to study human brain development 
and disease. We indicate that it is possible to develop a reliable in vitro model of both 
neurodevelopmental and neurodegenerative disorders to verify the disease phenotypes and 
uncover underlying mechanisms in 2D and 3D systems. This cellular model could offer novel 
approaches to therapeutic applications of complex neurological diseases taking scientists one 
step closer to treatment.  
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